ZOC2017217

Primary objective: To evaluate the efficacy of ZOC2017217 eye drops in patients with early and middle-stage senile cataract based on the change of best corrected distance visual acuity (BCDVA) from baseline at week 12, and to explore the appropriate dosing regimen. Secondary objectives: 1. To evaluate the efficacy of ZOC2017217 eye drops in patients with early and middle-stage senile cataract based on secondary efficacy endpoints such as the change of uncorrected distance visual acuity (UCDVA) from baseline and the change of lens opacity score from baseline. 2. To evaluate the safety of ZOC2017217 eye drops in patients with early and middle-stage senile cataract. 3. To evaluate the blood concentration of ZOC2017217 eye drops in patients with early and middle-stage senile cataract. Exploratory objective: To evaluate the change of near added diopters (ADD) of ZOC2017217 eye drops in patients with early and middle-stage senile cataract from baseline.